MD Anderson Cancer Center
Iressa As Effective As Chemotherapy for Lung Cancer Treatment – CNL
Groundbreaking study results suggest the drug Iressa has been proven to be just as effective as chemotherapy for treating lung cancer. The Iressa in Non-small cell lung cancer Trial Evaluating REsponse and Survival versus Taxotere (INTERST) study was a randomized phase III clinical trial evaluating the survival rate between IRESSA and docetaxel chemotherapy. These findings represent the first time an oral therapy has been tested head-to-head against standard therapy and surprising biomarker results. Edward Kim, M.D., a lead researcher in the INTERST Study, discusses the international Phase III clinical trial.
Accessibility shortcut keys (H) Shortcuts     View Transcripts Transcripts
This audio is avaliable in a Flash version only and requires an updated Flash player. Please update your Flash player or watch on a device which supports Flash. Flash Player Help . For additional recordings, please visit our online search for additional media resources.

Title: Iressa As Effective As Chemotherapy for Lung Cancer Treatment – CNL
Summary: Groundbreaking study results suggest the drug Iressa has been proven to be just as effective as chemotherapy for treating lung cancer. The Iressa in Non-small cell lung cancer Trial Evaluating REsponse and Survival versus Taxotere (INTERST) study was a randomized phase III clinical trial evaluating the survival rate between IRESSA and docetaxel chemotherapy. These findings represent the first time an oral therapy has been tested head-to-head against standard therapy and surprising biomarker results. Edward Kim, M.D., a lead researcher in the INTERST Study, discusses the international Phase III clinical trial.
Accessibility shortcut keys (H) Shortcuts     View Transcripts Transcripts
Keywords:
Transcript: View Transcripts Transcripts